Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

BACKGROUND: Anti‐drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and adverse events. OBJECTIVE: To identify risk factors for ADAb in the early phase of infliximab treatment. METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Brun, Marthe Kirkesæther, Goll, Guro Løvik, Jørgensen, Kristin Kaasen, Sexton, Joseph, Gehin, Johanna Elin, Sandanger, Øystein, Olsen, Inge Christoffer, Klaasen, Rolf Anton, Warren, David John, Mørk, Cato, Kvien, Tore K., Jahnsen, Jørgen, Bolstad, Nils, Haavardsholm, Espen A., Syversen, Silje Watterdal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545769/
https://www.ncbi.nlm.nih.gov/pubmed/35411981
http://dx.doi.org/10.1111/joim.13495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545769/
https://www.ncbi.nlm.nih.gov/pubmed/35411981
http://dx.doi.org/10.1111/joim.13495

Ejemplares similares